Adaptimmune Therapeutics - ADAP Stock Forecast, Price & News

5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Adaptimmune Therapeutics in the last twelve months. There are currently 2 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" ADAP shares.
View ADAP analyst ratings or view top-rated stocks.

5 brokerages have issued twelve-month price objectives for Adaptimmune Therapeutics' shares. Their ADAP share price forecasts range from $3.00 to $10.00. On average, they predict the company's share price to reach $6.00 in the next twelve months. This suggests a possible upside of 263.6% from the stock's current price.
View analysts price targets for ADAP or view top-rated stocks among Wall Street analysts.

Adaptimmune Therapeutics' stock was trading at $1.46 at the start of the year. Since then, ADAP stock has increased by 13.0% and is now trading at $1.65.
View the best growth stocks for 2023 here.

Adaptimmune Therapeutics saw a decline in short interest in the month of January. As of January 15th, there was short interest totaling 2,710,000 shares, a decline of 8.1% from the December 31st total of 2,950,000 shares. Based on an average trading volume of 536,000 shares, the days-to-cover ratio is presently 5.1 days. Approximately 1.9% of the shares of the stock are sold short.
View Adaptimmune Therapeutics' Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Monday, March 13th 2023.
View our ADAP earnings forecast.

Adaptimmune Therapeutics plc (NASDAQ:ADAP) announced its earnings results on Thursday, November, 4th. The biotechnology company reported ($0.30) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.26) by $0.04. The biotechnology company had revenue of $1.20 million for the quarter, compared to analyst estimates of $1.20 million. Adaptimmune Therapeutics had a negative net margin of 998.26% and a negative trailing twelve-month return on equity of 112.16%. During the same quarter last year, the company posted ($0.23) EPS.

6 employees have rated Adaptimmune Therapeutics Chief Executive Officer Adrian Rawcliffe on Glassdoor.com. Adrian Rawcliffe has an approval rating of 100% among the company's employees. This puts Adrian Rawcliffe in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Based on aggregate information from My MarketBeat watchlists, some companies that other Adaptimmune Therapeutics investors own include Zynerba Pharmaceuticals (ZYNE), CA (CA), Endologix (ELGX), Brainstorm Cell Therapeutics (BCLI), Second Sight Medical Products (EYES), Shopify (SHOP), Micron Technology (MU), BlackRock (BLK), Cara Therapeutics (CARA) and Chipotle Mexican Grill (CMG).

(ADAP) raised $150 million in an initial public offering (IPO) on Wednesday, May 6th 2015. The company issued 9,400,000 shares at a price of $15.00-$17.00 per share. BofA Merrill Lynch, Cowen and Company and Leerink Partners acted as the underwriters for the IPO and Guggenheim Securities was co-manager.

Adaptimmune Therapeutics trades on the NASDAQ under the ticker symbol "ADAP."

Adaptimmune Therapeutics' stock is owned by many different institutional and retail investors. Top institutional investors include Baillie Gifford & Co. (10.48%), Key Client Fiduciary Advisors LLC (0.18%), Vigilare Wealth Management (0.02%), Simplex Trading LLC (0.00%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Adrian Rawcliffe, Cintia Piccina, Elliot Norry, Gavin Wood, James Noble, John Lunger, Lawrence M Alleva, William C Bertrand Jr and William C Bertrand, Jr.
View institutional ownership trends.

Shares of ADAP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of ADAP stock can currently be purchased for approximately $1.65.

Adaptimmune Therapeutics (NASDAQ:ADAP) has a market capitalization of $270.32 million and generates $6.15 million in revenue each year. The biotechnology company earns $-158,090,000.00 in net income (profit) each year or ($1.09) on an earnings per share basis.

The company employs 494 workers across the globe.

Adaptimmune Therapeutics' mailing address is 60 JUBILEE AVENUE MILTON PARK OXFORDSHIRE, ABINGDON X0, OX14 4RX. The official website for the company is www.adaptimmune.com. The biotechnology company can be reached via phone at 441235430000, via email at ir@adaptimmune.com, or via fax at 44-12-3543-0001.